ACIS INVESTMENT INTELLIGENCE · GROWTH & QUALITY VALUE · 010
HSBC's 18.8% Nine-Month RoTE Confirms Quality—But 1.94× TNAV Is Not Yet a Great Price
ACIS Investment Intelligence | Growth & Quality Value Scan | Issue 010 | 27 October 2026
HSBC reported $10.0bn of third-quarter profit before tax and $18.7bn of revenue excluding notable items on 27 October 2026. Annualised RoTE was 18.2% for Q3 and 18.8% for the first nine months excluding notable items. Banking NII, a 1.60% NIM and continued dividends and buybacks pass the quality gate. At a $91.21 ADR, five ordinary shares per ADS and $9.41 of TNAV per ordinary share, however, P/TNAV is about 1.94×. That price requires durable high returns and leaves insufficient margin of safety. HSBC moves from Quality Core / Do Not Chase to Quality Core / Valuation & Revision Gate, not to a new Quality Value candidate. New Growth: 0. New Quality Value: 0.
Public research | Full access
Coverage: HSBC | Standard Chartered | AIA | Manulife | JPM | BAC | AIG | MSFT | GOOGL | ANET | XOM | CVX | DUK | SO. Price snapshots principally use the 26 October 2026 U.S. close. Securities in different currencies are not compared without adjustment.
HSBC reported $10.0bn of third-quarter profit before tax and $18.7bn of revenue excluding notable items on 27 October 2026. Annualised RoTE was 18.2% for Q3 and 18.8% for the first nine months excluding notable items. Banking NII, a 1.60% NIM and continued dividends and buybacks pass the quality gate. At a $91.21 ADR, five ordinary shares per ADS and $9.41 of TNAV per ordinary share, however, P/TNAV is about 1.94×. That price requires durable high returns and leaves insufficient margin of safety. HSBC moves from Quality Core / Do Not Chase to Quality Core / Valuation & Revision Gate, not to a new Quality Value candidate. New Growth: 0. New Quality Value: 0.
The one-minute brief
The material change is a cleaner distinction between company quality and purchase price. HSBC's spread income, wealth and transaction-banking fees, 18%-plus RoTE and capital return confirm better corporate value capture. Yet credit charges now include a US fraud-related sponsor exposure, Hong Kong commercial real estate and Middle East uncertainty; CET1 also declined sequentially and the ADR is near its representative six-month high. Standard Chartered reports tomorrow, while MSFT, GOOGL and ANET are entering earnings gates. The correct action is to wait for revisions and a valuation reset, not front-run them.
Audio transcript
Quality is confirmed, but the price gate has not cleared. HSBC delivered ten billion dollars of third-quarter profit before tax excluding notable items. Annualised RoTE was eighteen point two percent for the quarter and eighteen point eight percent for nine months. At ninety-one dollars and twenty-one cents per ADR, five ordinary shares per ADS and nine dollars and forty-one cents of TNAV per ordinary share, the stock trades near one point nine four times TNAV. That valuation requires durable high returns, while the drawdown is far below the twenty percent review trigger. HSBC remains behind a valuation and revisions gate. Standard Chartered, Microsoft, Alphabet and Arista are all approaching earnings events. There are no new Growth or Quality Value candidates, and every real action requires Human Approval.
Selection
Strongest Growth: none | Strongest Quality Value: none
State update
HSBC: Quality Core / Do Not Chase → Quality Core / Valuation & Revision Gate
Portfolio boundary
Alpha sleeve ≤15%, single Alpha ≤3%; this report authorizes no capital
01 · CANONICAL MARKET CONTEXT
Reuse valid evidence; do not manufacture a signal
Broad FOMO
- Latest valid
- 49
- Prior
- 38
- Change
- +11
- State
- Normal
- Confidence
- Medium
- As of
- 2026-10-21
- Mode
- Reused / No Recompute
AI Crowding
- Latest valid
- 75
- Prior
- 78
- Change
- -3
- State
- High
- Confidence
- Medium
- As of
- 2026-10-21
- Mode
- Reused / No Recompute
Market Breadth
- Latest valid
- 52
- Prior
- 33
- Change
- +19
- State
- Improving
- Confidence
- Medium
- As of
- 2026-10-21
- Mode
- Reused / No Recompute
This issue does not recompute market psychology. The Canonical Evidence Resolver carries forward the still-valid 21 October values: Broad FOMO 49, AI Crowding 75 and Market Breadth 52. CCOS was 37 on 26 October under Restrictive × Defensive Rotation. Context is not a trading signal.
02 · INDUSTRY-FIRST FUNNEL
No forced candidate before earnings gates
| Bucket | Dynamic universe | Gate | New candidates | Reason |
|---|---|---|---|---|
| Financials and insurance | HSBC, STAN, AIA, MFC; JPM/BAC as quality benchmarks | HSBC new results merit deep work | 0 | HSBC price gate fails; STAN reports next day |
| Energy and utilities | XOM, CVX, DUK, SO | Mid-cycle oil, leverage, FCF and regulatory recovery | 0 | No new mismatch clears all gates |
| Quality tech dislocation | MSFT, GOOGL, ANET | AI revenue → capex/leases → CFO/FCF → ROIC | 0 | All three face imminent earnings gates |
| P2 healthcare | Devices, tools, mature pharma, services and payors | Fundamentals + valuation mismatch + verifiable catalyst | 0 | No triple confirmation |
| P2 REIT | Reuse Physical Economy and Real Assets | P/FFO, P/AFFO, NOI, NAV, cap rate and refinancing | 0 | Do not use ordinary P/E for REITs |
Decision Board | Prior → current
| Asset | Prior | Current | Change | Evidence | Next gate |
|---|---|---|---|---|---|
| HSBC | Quality Core / Do Not Chase | Quality Core / Valuation & Revision Gate | Quality evidence up; selection stage unchanged | $10.0bn Q3 ex-notables PBT, 18.2% Q3 RoTE and 18.8% 9M RoTE; ~1.94× TNAV prices in durability | EPS revisions, credit cost, CET1, wealth NNM and a 1.30–1.55× TNAV research zone |
| Standard Chartered | Watch / Re-screen | Event Pending / Q3 Gate | No front-running tomorrow's report | 17.6% H1 RoTE, buyback and wealth growth support quality; Q3 is not yet published | 28 October revenue, NIM, credit cost, CET1, buyback and P/TBV |
| AIA | Alpha Trial Candidate | Same / No New Capital | Existing research state retained | H1 VONB and operating-ROE evidence remains strong; no like-for-like valuation trigger | VONB/APE, free surplus, capital return, HK valuation and FX |
| Manulife | Valuation Watch | Same | No stage change | Core earnings, Asia growth and LICAT still support quality; relative value awaits refresh | Q3 core earnings, ROE, LICAT, Asia NBV and capital return |
| MSFT / GOOGL / ANET | Quality Tech Watch | Earnings Gate / No Upgrade | Freeze upgrades before results | MSFT and GOOGL report 28 October; ANET reports 3 November | AI revenue, capex/leases, CFO/FCF, incremental ROIC and EPS revisions |
| Energy / Utilities | P1 Dynamic Scan | No Formal Candidate | No material upgrade | Price and trailing multiples cannot replace mid-cycle commodity, leverage, regulation and cash-flow work | Mid-cycle oil, FCF cover, net debt, returns and regulatory recovery |
| Healthcare / REIT | P2 Low-intensity Radar | No Upgrade | Triple confirmation absent | Fundamental improvement, valuation mismatch and a verifiable catalyst are not all present | Sector-specific valuation, balance sheet, revisions and catalyst |
03 · HSBC EARNINGS INTELLIGENCE
Quality passes; contradictions remain
| Metric | Current | Comparison | Meaning |
|---|---|---|---|
| Q3 2026 PBT excluding notable items | $10.0bn | +10% YoY at constant currency | Quality strengthened |
| Q3 revenue excluding notable items | $18.7bn | +5% YoY | Banking NII and fees grew |
| Annualised RoTE | Q3 18.2% | 9M 18.8% | Keep periods separate | Quality gate passes |
| NIM | 1.60% | +3bp for 9M | Spread resilience |
| CET1 | 13.9% | −20bp QoQ | Adequate, not expanding |
| Capital return | $0.10 ordinary dividend + up to $1bn new buyback | Prior $1bn completed | Returns continue |
| Credit contradiction | ~$0.5bn US fraud-related sponsor plus ~$0.3bn HK CRE and Middle East uncertainty | Recognized in ECL | RoTE is not risk-free |
04 · VALUATION AND EXPECTATIONS
A strong bank can still be fully priced
| Scenario | RoTE | Payout | Terminal P/TNAV | Total value incl. dividends | 4-year CAGR |
|---|---|---|---|---|---|
| Tail | 10% | 30% | 0.90× | ~$49 | ~−14% |
| Bear | 13% | 50% | 1.25× | ~$89 | ~−1% |
| Base | 15.5% | 50% | 1.70× | ~$124 | ~8% |
| Bull | 18% | 50% | 2.20× | ~$165 | ~16% |
The four-year sensitivity starts at $91.21 per ADS and uses $9.41 of TNAV per ordinary share and five ordinary shares per ADS. RoTE, payout and terminal P/TNAV are scenarios, with simplified dividends included; outputs are not price targets. Roughly 1.94× current P/TNAV requires about 16.6% sustainable RoTE assuming 10% cost of equity and 3% growth. A 1.30–1.55× research zone equates to roughly $61–$73 per ADS and is not a buy order.
05 · LIKE-FOR-LIKE FINANCIALS
HSBC has the newest evidence—not the best entry price
| Company | Return quality | Growth evidence | Capital | Return of capital | Valuation/state |
|---|---|---|---|---|---|
| HSBC | 9M ex-notables RoTE 18.8% | NIM 1.60%; revenue +5% | CET1 13.9% | Dividend + new $1bn buyback | ~1.94× TNAV; Gate |
| STAN | H1 RoTE 17.6% | Wealth and cross-border growth | CET1 14.2% | $1bn H1 buyback | Q3 tomorrow; Event Pending |
| AIA | H1 operating ROE ~17.5% | VONB $3.2bn | Capital basis differs | Dividend growth and buyback | Like-for-like value pending |
| Manulife | Q2 core ROE 16.3% | Asia core earnings +21% | LICAT 136% | Regular return framework | Like-for-like value pending |
06 · P1 AND P2 SCAN
Watchlists narrow; standards do not
| Bucket | Current conclusion | Next validation |
|---|---|---|
| Financials | HSBC has the strongest new evidence; quality passes, price fails | Wait for STAN Q3 and HSBC revisions |
| Energy and utilities | No formal upgrade; P/E does not replace cycle and debt work | Refresh oil, FCF cover and regulation |
| Quality tech | No pre-earnings upgrade; GOOGL's low trailing P/E alone is not Great Price | MSFT/GOOGL 28 Oct, ANET 3 Nov |
| Healthcare P2 | No triple confirmation | Next formal results and regulatory catalysts |
| REIT P2 | No triple confirmation; DUK's distorted trailing P/E is not a value signal | P/FFO, P/AFFO, NOI, NAV, cap rates and refinancing |
07 · CORE BETA AND ALPHA GOVERNANCE
No new risk budget
| Layer | State | Implication |
|---|---|---|
| Core Beta | QQQ Yellow / No Upgrade | Dense earnings calendar and AI Crowding 75 require cash-return validation |
| Alpha Sleeve | No New Allocation | Total Alpha ≤15%, single Alpha ≤3%; it need not be fully used |
| Position Governance | No Exception | Any >3% requires prior Human Exception Review; legacy positions do not migrate automatically |
| Options | No Authorization | Short puts assume immediate assignment and funded cash; covered calls require deliverable shares |
| Human Decisions | None Requested | No trade, rebalance or client action is authorized |
THESIS → EVIDENCE → UPDATE
Quality improved; expected return did not
Thesis
Returns in quality financials require normalized RoTE, capital return and purchase P/TNAV to work together; high RoTE cannot replace margin of safety.
Evidence
HSBC reported $10.0bn of third-quarter profit before tax and $18.7bn of revenue excluding notable items on 27 October 2026. Annualised RoTE was 18.2% for Q3 and 18.8% for the first nine months excluding notable items. Banking NII, a 1.60% NIM and continued dividends and buybacks pass the quality gate. At a $91.21 ADR, five ordinary shares per ADS and $9.41 of TNAV per ordinary share, however, P/TNAV is about 1.94×. That price requires durable high returns and leaves insufficient margin of safety. HSBC moves from Quality Core / Do Not Chase to Quality Core / Valuation & Revision Gate, not to a new Quality Value candidate. New Growth: 0. New Quality Value: 0.
Update
HSBC's quality evidence improves, but its selection state only refines from Do Not Chase to Valuation & Revision Gate. STAN enters an earnings gate. AIA and Manulife are unchanged, and no formal candidate emerges from tech, energy, utilities, healthcare or REITs.
RISKS AND 90-DAY REVIEW
Return durability
The current multiple requires durable mid-to-high-teens RoTE; rates, deposit beta and credit cost can lower it.
Credit concentration
The US sponsor exposure, Hong Kong CRE and Middle East uncertainty contradict a risk-free RoTE reading.
Comparability
Bank, life-insurance and diversified-financial RoTE, ROE, NBV and capital ratios are not mechanically comparable.
Event risk
STAN, MSFT, GOOGL and ANET have not reported this cycle; pre-earnings revisions would create false precision.
Model risk
P/TNAV scenarios are highly sensitive to cost of equity, growth, payout and terminal multiple; they are not targets.
| Window | Checks |
|---|---|
| 0–7 days | STAN Q3; MSFT and GOOGL results; ANET 3 November setup; HSBC consensus revisions |
| 8–30 days | HSBC credit cost, wealth NNM and buyback; AIA/MFC updates; energy mid-cycle assumptions |
| 31–90 days | RoTE durability, CET1, capital return, tech AI-revenue-to-FCF bridge and P2 triple confirmation |
FAQ
Five questions that prevent a price-only decision
Why is HSBC not the Quality Value pick?
Quality passes, but roughly 1.94× TNAV near a six-month high leaves insufficient margin of safety.
Can 18.8% RoTE simply be capitalized?
No. It is the nine-month ex-notables measure and must survive rate, credit, cost and capital-return tests.
Has HSBC triggered drawdown re-entry review?
No. Against a representative six-month high near $95.22, the drawdown is about 4%, below the 20% and 30% thresholds.
Why not front-run Standard Chartered?
Its formal Q3 data arrive on 28 October; inferring new EPS revisions from old data violates the evidence rule.
Does this report require a portfolio action?
No. Every real investment, trade, position and client action requires Human Approval.
SOURCES AND CONTINUITY
Primary disclosures and canonical research
Standard Chartered | Q3 2026 schedule ↗
Standard Chartered | H1 2026 presentation ↗
Microsoft | FY2027 Q1 earnings event ↗
Continue reading
Evidence through 19:00 Beijing time on 27 October 2026. Public content uses formal disclosures, verifiable market snapshots and clearly labeled research assumptions. It excludes real holdings, costs, trade plans, client data, internal procedures, prompts, scoring formulae and credentials. Scenarios are not targets, offers or personalized advice.